These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 28237194)

  • 1. Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value Frameworks.
    Cohen JT; Anderson JE; Neumann PJ
    Value Health; 2017 Feb; 20(2):193-199. PubMed ID: 28237194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approaches to Capturing Value in Oncology.
    Walter E
    Recent Results Cancer Res; 2019; 213():85-108. PubMed ID: 30543009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs.
    Bentley TGK; Cohen JT; Elkin EB; Huynh J; Mukherjea A; Neville TH; Mei M; Copher R; Knoth R; Popescu I; Lee J; Zambrano JM; Broder MS
    Value Health; 2017 Feb; 20(2):200-205. PubMed ID: 28237195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6].
    Willke RJ; Neumann PJ; Garrison LP; Ramsey SD
    Value Health; 2018 Feb; 21(2):155-160. PubMed ID: 29477393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why Value Framework Assessments Arrive at Different Conclusions: A Multiple Myeloma Case Study.
    Westrich K; Buelt L; Dubois RW
    J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S28-S33. PubMed ID: 28535102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value Frameworks in Oncology: Comparative Analysis and Implications to the Pharmaceutical Industry.
    Slomiany M; Madhavan P; Kuehn M; Richardson S
    Am Health Drug Benefits; 2017 Jul; 10(5):253-260. PubMed ID: 28975009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1].
    Neumann PJ; Willke RJ; Garrison LP
    Value Health; 2018 Feb; 21(2):119-123. PubMed ID: 29477388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating Frameworks That Provide Value Measures for Health Care Interventions.
    Mandelblatt JS; Ramsey SD; Lieu TA; Phelps CE
    Value Health; 2017 Feb; 20(2):185-192. PubMed ID: 28237193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value-based medicine in oncology: the importance of perspective in the emerging value frameworks.
    Campolina AG
    Clinics (Sao Paulo); 2018 Dec; 73(suppl 1):e470s. PubMed ID: 30540119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions.
    Sculpher M; Claxton K; Pearson SD
    Value Health; 2017 Feb; 20(2):234-239. PubMed ID: 28237201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision Making.
    Waldeck AR; Botteman MF; White RE; van Hout BA
    J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S6-S12. PubMed ID: 28535105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in Measuring Cost and Value in Oncology: Making It Personal.
    Yu PP
    Value Health; 2016; 19(5):520-4. PubMed ID: 27565267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward a Hedonic Value Framework in Health Care.
    Basu A; Sullivan SD
    Value Health; 2017 Feb; 20(2):261-265. PubMed ID: 28237206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
    Lakdawalla DN; Chou JW; Linthicum MT; MacEwan JP; Zhang J; Goldman DP
    JAMA Oncol; 2015 May; 1(2):196-202. PubMed ID: 26181023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value assessment of immuno-oncology in the treatment of rare tumors in the era of accelerated conditional approvals.
    Lanitis T; Ambavane A; Zheng Y; Schlichting M; Phatak H
    Future Oncol; 2019 Dec; 15(35):4057-4067. PubMed ID: 31687852
    [No Abstract]   [Full Text] [Related]  

  • 16. As Value Assessment Frameworks Evolve, Are They Finally Ready for Prime Time?
    Dubois RW; Westrich K
    Value Health; 2019 Sep; 22(9):977-980. PubMed ID: 31511186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines and Value-Based Decision Making: An Evolving Role for Payers.
    McCauley JL
    N C Med J; 2015; 76(4):243-6. PubMed ID: 26509518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence-Based and Value-Based Decision Making About Healthcare Design: An Economic Evaluation of the Safety and Quality Outcomes.
    Zadeh R; Sadatsafavi H; Xue R
    HERD; 2015; 8(4):58-76. PubMed ID: 26123968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.